How do I find recruiting Hepatocellular Carcinoma clinical trials?

Corterve aggregates actively recruiting Hepatocellular Carcinoma studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.

Are Hepatocellular Carcinoma clinical trials free to join?

Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.

Who can take part in a Hepatocellular Carcinoma clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.

Hepatocellular Carcinoma Clinical Trials

Hepatocellular Carcinoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for hepatocellular Carcinoma. Corterve aggregates actively recruiting Hepatocellular Carcinoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.

Browse all Hepatocellular Carcinoma trials Take the free assessment

Recruiting Hepatocellular Carcinoma studies

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
NCT07059494PHASE4Icahn School of Medicine at Mount SinaiNew York, New York
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941PHASE1BeOne MedicinesGoodyear, Arizona
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT06066138PHASE1National Cancer Institute (NCI)Bethesda, Maryland
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841PHASE1Compass TherapeuticsOmaha, Nebraska
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT07285044PHASE2Mayo ClinicJacksonville, Florida
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
NCT06811116PHASE1, PHASE2National Cancer Institute (NCI)Irvine, California
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
NCT06915753PHASE1Tyra Biosciences, IncLos Angeles, California
IDOV-Immune for Advanced Solid Tumors
NCT06910657PHASE1ViroMissile, Inc.St Louis, Missouri
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076PHASE1, PHASE2Bristol-Myers SquibbDuarte, California
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762PHASE1Seagen, a wholly owned subsidiary of PfizerBirmingham, Alabama
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012PHASE1, PHASE2PfizerLos Angeles, California
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
NCT06899152NAMontefiore Medical CenterThe Bronx, New York

See all 113 recruiting Hepatocellular Carcinoma trials →

Hepatocellular Carcinoma trials by state

Hepatocellular Carcinoma trials by metro

Frequently asked questions

How do I find recruiting Hepatocellular Carcinoma clinical trials?: Corterve aggregates actively recruiting Hepatocellular Carcinoma studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
Are Hepatocellular Carcinoma clinical trials free to join?: Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
Who can take part in a Hepatocellular Carcinoma clinical trial?: Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.